

Interaction between warfarin and functional foods derived from *Bacillus subtilis natto*

Masahito Hitosugi, Xia Zhu, Hisayoshi Kato, Shogo Tokudome

Interaction between warfarin and functional foods derived from *Bacillus subtilis natto*

Masahito Hitosugi¹, Xia Zhu², Hisayoshi Kato², Shogo Tokudome¹

Introduction

Thrombotic diseases have been increasing recently and are said to account for approximately 30% of all causes of death among Japanese people. Potassium warfarin (hereinafter referred to as “wf”), a preventive for thrombosis, is the most commonly used oral coumarin anticoagulant and is known to have a number of interactions with foods and other drugs. For example, patients receiving wf must pay attention to the intake of foods and drugs containing vitamin K (hereinafter referred to as “vit K”), because vit K in large doses may cancel the effectiveness of wf. The anticoagulant effect of wf consists of negative action on the carboxylation of vit K and inhibition of the biosynthesis of the vit K-dependent blood coagulation factors in the liver. Drugs containing vit K include, in addition to vit K preparations, enteric nutrients, high-calorie transvenous nutritional infusions and menatetrenone—which is an anti-osteoporosis drug—and unless these drugs are administered, vit K is not delivered in drug form. However, vit K is contained in certain foods in large quantities, especially in natto which contains about 1 mg of vit K₂ per 100 g¹⁾. Natto, a traditional Japanese food, has been eaten from old times for the purpose of maintaining good health as it is a good source of B-complex vitamins. In addition, proteases and glycolytic enzymes produced by *Bacillus subtilis natto* have been found to have a variety of bioactivities²⁻⁴⁾. According to a national survey of natto consumption conducted in 2003 over the Internet, people who eat natto everyday accounted for 14.6% of respondents while those who have one or more servings of natto every two to three days accounted for 47.0%. The number of servings had also increased in 32.3% of respondents and the reasons cited included nutritional value and health benefits⁵⁾. While natto has thus been routinely consumed, patients taking wf are instructed to avoid the intake of natto to prevent interactions with vit K^{1,6)}.

Meanwhile, health foods have been flooding the market due to the health boom. A survey conducted among people 20 years of age or over showed that those with a history of consuming some type of health food accounted for 76% of respondents⁷⁾. It is therefore possible that patients taking wf are consuming health foods, and as health foods high in vit K

¹ Dokkyo University School of Medicine, Department of Legal Medicine

² Department of Research and Development, Daiwa Pharmaceutical Co., Ltd.

have been reported to inhibit the effect of wf, this is resulting in the aggravation of conditions⁸⁾. Patients taking wf must accordingly pay close attention to the use of health foods. Health foods containing vit K in relatively large quantities include “nattokinase”, “chlorella” and “green juice”. It is important to identify the vit K content in health foods by checking ingredient labels to consider interactions with wf^{1,6,9)}.

NKCP[®] is one of the health foods produced from the culture of *B. subtilis natto*. NKCP[®] has anticoagulant and thrombolytic effects on human blood and has demonstrated a significant shortening of the euglobulinlysis time and improvement of neck stiffness after ingestion in clinical studies^{4,11)}. However, some patients taking wf have had concerns about interactions and chemists filling prescriptions have had difficulties determining whether they should recommend the taking of NKCP[®] as it is derived from *B. subtilis natto*. To help resolve these concerns, a quantitative determination of vit K₂ in NKCP[®] was performed, as follows.

1. Subject and Method

1.1. Target substance

The sample used was NKCP[®] extracted from a culture of *B. subtilis natto*. The extraction process included centrifugal separation of a culture of *B. subtilis natto* to remove solids and bacterial bodies, ultrafiltration of the supernatant to remove substances of a molecular weight of 3,000 or less, and vacuum drying. NKCP[®] has a molecular weight of 34,134 and has been shown in amino acid analysis to be a fragment of Bacillopeptidase F, a protease excreted by *B. subtilis*. Basic studies have demonstrated a thrombolytic effect on artificial thrombosis and a coagulation inhibitory effect on human blood, as well as a coagulation inhibitory effect in rats given enteral administration^{4,11)}.

p. 2

1.2. Method

Isopropyl alcohol was added to NKCP[®] to extract vit K₂, which was determined by high-performance liquid chromatography (HPLC). The vit K₂ was then reduced by a reduction column to generate fluorescence and measured by a fluorescence detector. The HPLC conditions are shown in Table 1.

Table 1 Measurement conditions using the HPLC method

Analytical column	Fincpaksil C18 (4.6 × 250 mm)
Reduction column	Platinum black column (4.0 × 10 mm)
Mobile phase	Methanol
Flow rate	0.7 ml./min
Detector	Fluorescence detector (Ex: 320 nm; Em: 430 nm)

2. Results

The results of the measurement of vit K₂ in NKCP[®] are presented in Table 2. Five of the nine most recent lots were below the detection limit (10 µg/100 g). Concerning these lots, the average vit K₂ content per 100 g of NKCP[®], measured assuming the content to be 10 µg/100 g, was 18.9±10.2 µg. The average vit K₂ content in 250 mg of NKCP[®], representing the average daily intake of NKCP[®], was 0.05 µg or less.

Table 2 vit K₂ content in 100 g of NKCP[®]

Lot	vit K ₂ content (µg)
1	<10
2	<10
3	<10
4	<10
5	30
6	29
7	26
8	35
9	<10
Mean ± SD	18.9 ± 10.2*

(*: <10 was calculated as representing 10 µg)

3. Discussion

The daily requirement for vit K in humans is met by dietary sources such as from green and yellow vegetables (males: 0.065 mg; females: 0.055 mg) and the vit K produced by enteric bacteria¹²⁾. In patients taking wf, a daily intake of 0.2 mg or more of vit K may result in a significant departure from the prothrombin time (international normalised ratio)—which is used for evaluating anticoagulant effect—from the wf treatment range within 14 days, and a daily intake of 1 mg or more of vit K is said to influence the effectiveness of wf¹³⁾.

As shown in this study, an average daily intake of 250 mg of NKCP[®] contains only 0.05 µg or less of vit K₂. This value is below the aforementioned average daily intake from dietary sources, so if taken on a daily basis, NKCP[®] may not have implications for the effectiveness of wf. Natto can impact upon the effectiveness of wf because it contains vit K₂ in considerable quantities and following ingestion, *B. subtilis natto* continues to produce vit K₂ in the intestine. NKCP[®], which is derived from the culture of *B. subtilis natto*, was found to be virtually deprived of vit K₂ as well as bacterial bodies during the production process.

NKCP[®] must be verified for safety and efficacy as it is used as a health food. Previous studies, including pre-clinical studies, subacute and chronic ingestion studies in humans, have demonstrated its safety^{4,11)}. This study has confirmed that because it contains an extremely small quantity of vit K₂, NKCP[®] may not decrease the effectiveness of wf if taken routinely by patients receiving wf.

Conclusion

Generally speaking, patients receiving wf must pay attention to the use of health foods as well as other drugs. The ingredients of health foods suspected of containing vit K or of being derived from *B. subtilis natto* must be examined prior to ingestion, and those containing vit K in large quantities must be avoided. While this study was targeted at NKCP[®], it will be important to identify ingredients in health foods as a whole and to scientifically verify their safety and efficacy.

References

- 1) Hasegawa A: Antithrombotic medication: *Clinical and Medication* 19, 882-885 (2000)
 - 2) Sumi H, Hamada H, Tsushima H, Muraki H: A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. *Experimenta* 43, 1110-1111 (1987)
 - 3) Kashiwabara K, Nio N, Kubota K: Purification of protease from natto and its characteristic: *The Japanese Society for Food Science and Technology* 48, 134-137 (2001)
 - 4) Omura K, Kaketani K, Maeda H, Hitosugi M: Effect of protein from *Bacillus subtilis natto* on human blood coagulation and fibrinolysis: *Japan Biorheology* 18, 44-51 (2004)
 - 5) Japan Natto Cooperative Society Federation: National consumer study of natto 2003: *Food Sciences* 10, 46-56 (2003)
 - 6) Ito Y, Oi K: Warfarin potassium and vitamin K: *Iyaku Journal* 38, 201-205 (2002)
 - 7) Japan Supplement Association: Report of “consumer inquiry survey on supplements”, a cooperation study with Japan Management Association
- Website: www.j-sup.com/chousakekka.html
- 8) Matsui K, Goso Y, Nakagawa K, Hirai T, Kameyama T, Kumazawa T, Asanoi E, Inoue H: A case of mitral stenosis developing femoral artery embolism from weakening of warfarin action after taking health food: *Heart* 33, 525-528 (2001)
 - 9) Hata K, Mochida R: Risk study of mutual action between health food sold over the internet and warfarin: *Iyaku to Yakugaku* 51, 343-345 (2004)
 - 10) Saiki A, Nakamura T, Masada M: Dosing guideline of vitamin K containing-preparation toward patients with warfarin administration: *Iyaku Journal* 39, 2072-2079 (2003)
 - 11) Omura K, Hitosugi M, Zhu X, Ikeda M, Maeda H, Tokutome S. A newly derived protein from *Bacillus subtilis natto* with both antithrombotic and fibrinolytic effects. *J Pharmacol Sci* 99, 247-251 (2005)
 - 12) The 6th revision of Japanese nutritional requirements (June 28, 1999)
 - 13) Crowther MA, *et al.*: Treatment of warfarin-associated coagulopathy with oral Vitamin K: a randomised controlled trial. *Lancet* 356, 1551-1553 (2000)

Masahito Hitosugi

1994: Graduated from Jikei University School of Medicine, worked at Kawasaki Municipal Hospital, department of internal medicine

2000: Graduated from Jikei University School of Medicine Postgraduate School, Medical Research, doctor's course, Assistant at the school

2002-: Assistant professor at Dokkyo University School of Medicine, Department of Legal Medicine

Specialty/ research topics: Condition analysis of sudden death caused by thrombotic disease, preventative medicine for external factor, and legal medicine in general

Recent research and activities: Elucidating preventative effect of *Bacillus subtilis natto* on thrombotic disease, etc.

Author/ papers: Nattoprotease -health maintenance series- Vol. 3, *Japan Functional Food Research Association* (2006), A newly derived protein from *bacillus subtilis natto* with both antithrombotic and fibrinolytic effects. *J Pharmacol Sci* 99, 247-251 (2005), Effect of protein from *Bacillus subtilis natto* on human blood coagulation and fibrinolysis: *Japan Biorheology* 18, 44-51 (2004), etc.